Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis

References

• Administration; FaD. FDA. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. Maryland: Silver Spring; 2013.
   Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013 Sep;19(9):E377–85. PubMed PMID: 23663184.
   PubMed Web of Science ®Google Scholar
• Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013 May 30;13(252). PubMed PMID: 23721377; PubMed Central PMCID: PMCPMC3679727. DOI:10.1186/1471-2334-13-252
   PubMedGoogle Scholar
• Jaaskelainen IH, Hagberg L, From J, et al. Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance – a retrospective population based study from Finland and Sweden. Clin Microbiol Infect. 2016 Apr;22(4):383e1–383 e10. PubMed PMID: 26806138.
   Web of Science ®Google Scholar
• Shen HN, Lu CL. Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study. BMC Infect Dis. 2010 Jun 4;10:151. PubMed PMID: 20525332; PubMed Central PMCID: PMCPMC2894834.
   PubMed Web of Science ®Google Scholar
• Zhao C, Liu Y, Zhao M, et al. Characterization of community acquired Staphylococcus aureus associated with skin and soft tissue infection in Beijing: high prevalence of PVL+ ST398. PLoS One. 2012;7(6):e38577. PubMed PMID: 22701673; PubMed Central PMCID: PMCPMC3368899
   PubMed Web of Science ®Google Scholar
• Dabrowski H, Wickham H, De S, et al. Clinical outcomes of teicoplanin use in the OPAT setting. Int J Antimicrob Agents. 2020 Mar;55(3):105888. PubMed PMID: 31923571; PubMed Central PMCID: PMCPMC7068648.
   PubMed Web of Science ®Google Scholar
• Pulido-Cejudo A, Guzman-Gutierrez M, Jalife-Montano A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 2017 Sep 4;(5):143–161. PubMed PMID: 28959445; PubMed Central PMCID: PMCPMC5593224. DOI:10.1177/2049936117723228.
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005 Nov 15;41(10):1407–1415. PubMed PMID: 16231250.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169–2179. PubMed PMID: 24897082.
   PubMed Web of Science ®Google Scholar
• Dalmastri C, Gastaldo L, Marcone GL, et al. Classification of Nonomuraea sp. ATCC 39727, an actinomycete that produces the glycopeptide antibiotic A40926, as Nonomuraea gerenzanensis sp. nov. Int J Syst Evol Microbiol. 2016 Feb;66(2):912–921. PubMed PMID: 26944798.
   PubMed Web of Science ®Google Scholar
• Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2008 Apr 1;65(7):599–610. PubMed PMID: 18359966.
   PubMed Web of Science ®Google Scholar
• Sosio M, Stinchi S, Beltrametti F, et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem Biol. 2003 Jun;10(6):541–549. PubMed PMID: 12837387.
   PubMedGoogle Scholar
• Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008 Feb 15;46(4):577–583. PubMed PMID: 18199045.
   PubMed Web of Science ®Google Scholar
• Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007 May;16(5):717–733. PubMed PMID: 17461743.
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005 Mar;55(Suppl 2):ii15–20. PubMed PMID: 15750032.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2008 Feb 6;(1):67–81. PubMed PMID: 18251665. DOI:10.1586/14787210.6.1.67.
   PubMed Web of Science ®Google Scholar
• PE R. Structure biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8(943–50):943–950.
   PubMedGoogle Scholar
• Johnson DM, Fritsche TR, Sader HS, et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006 Jun;27(6):557–560. PubMed PMID: 16698238.
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007 May;51(5):1633–1642. PubMed PMID: 17307987; PubMed Central PMCID: PMCPMC1855559.
   PubMed Web of Science ®Google Scholar
• Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother. 2004 Apr;48(4):1118–1123. PubMed PMID: 15047510; PubMed Central PMCID: PMCPMC375267.
   PubMed Web of Science ®Google Scholar
• Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother. 2006 Oct;58(4):802–805. PubMed PMID: 16891629.
   PubMed Web of Science ®Google Scholar
• Candiani G, Abbondi M, Borgonovi M, et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999 Aug;44(2):179–192. PubMed PMID: 10473224.
   PubMed Web of Science ®Google Scholar
• Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005 Mar;55(Suppl 2):ii21–4. PubMed PMID: 15750033.
   PubMedGoogle Scholar
• Malabarba A, Nicas TI, Thompson RC. Structural modifications of glycopeptide antibiotics. Med Res Rev. 1997 Jan;17(1):69–137. PubMed PMID: 8979249
   PubMed Web of Science ®Google Scholar
• Malabarba A, Ciabatti R, Scotti R, et al. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci. J Antibiot (Tokyo). 1995 Aug;48(8):869–883. PubMed PMID: 7592033.
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004 Mar;48(3):940–945. PubMed PMID: 14982787; PubMed Central PMCID: PMCPMC353075.
   PubMed Web of Science ®Google Scholar
• Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005 Mar;55(Suppl 2):ii25–30. PubMed PMID: 15750034.
   PubMedGoogle Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003 Nov 15;37(10):1298–1303. PubMed PMID: 14583862.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016 Mar 1;62(5):545–551. PubMed PMID: 26611777; PubMed Central PMCID: PMCPMC4741365.
   PubMed Web of Science ®Google Scholar
• Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019 Jun;17:60–65. PubMed PMID: 30797084.
   PubMed Web of Science ®Google Scholar
• Wilke M, Worf K, Preisendorfer B, et al. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data. GMS Infect Dis. 2019;7:Doc03. PubMed PMID: 31728264; PubMed Central PMCID: PMCPMC6839362.
   PubMedGoogle Scholar
• Campbell KC, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003 Apr;14(3):157–68;quiz 170–1. PubMed PMID: 12859140.
   Google Scholar
• Haidich AB. Meta-analysis in medical research. Hippokratia. 2010 Dec;14(Suppl1):29–37. PubMed PMID: 21487488; PubMed Central PMCID: PMCPMC3049418.
   PubMedGoogle Scholar
• Guest JF, Esteban J, Manganelli AG, et al. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis. PLoS One. 2017;12(11):e0187792. PubMed PMID: 29136035; PubMed Central PMCID: PMCPMC5685605.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018 Apr;24(4):361–368. PubMed PMID: 28882727; PubMed Central PMCID: PMCPMC5925741.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Mavros MN, Roussos N, et al. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc. 2012 Apr;87(4):349–363. PubMed PMID: 22469348; PubMed Central PMCID: PMCPMC3538415.
   PubMed Web of Science ®Google Scholar
• Logman JF, Stephens J, Heeg B, et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin. 2010 Jul;26(7):1565–1578. PubMed PMID: 20429820.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. PubMed PMID: 8721797.
   PubMedGoogle Scholar
• Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. www.cochrane-handbook.org.:
   Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998 Aug 22;352(9128):609–613. PubMed PMID: 9746022.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Sahm D, Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob. 2015 Apr 2;14:19. PubMed PMID: 25885674; PubMed Central PMCID: PMCPMC4389583.
   PubMed Web of Science ®Google Scholar
• Gonzalez PL, Rappo U, Akinapelli K, et al. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs Context. 2018;7:212559. PubMed PMID: 30574170; PubMed Central PMCID: PMCPMC6292452.
   PubMedGoogle Scholar
• Jagan N, Pendru R, Jyothinath K. Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections. Maedica (Buchar). 2018 Sep;13(3):208–212. PubMed PMID: 30568740; PubMed Central PMCID: PMCPMC6290182.
   PubMedGoogle Scholar
• McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE Trial. Infect Dis Ther. 2020 Mar 9;(1):53–67. PubMed PMID: 31713130; PubMed Central PMCID: PMCPMC7054506.
   PubMed Web of Science ®Google Scholar
• Laupland KB, Valiquette L. Outpatient parenteral antimicrobial therapy. Can J Infect Dis Med Microbiol. 2013;24(1):9–11. PubMed PMID: 24421785; PubMed Central PMCID: PMCPMC3630020.
   PubMed Web of Science ®Google Scholar
• Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) and the general physician. Clin Med (Lond). 2013 Oct;13(5):495–499. PubMed PMID: 24115709; PubMed Central PMCID: PMCPMC4953803.
   PubMed Web of Science ®Google Scholar